PDSB PDS Biotechnology Corporation Common Stock
XNAS
1.07
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
PDSB
$1.07
—
Key stats
$1.07
Pre-market
$1.06
-0.47%
- 52-Week Range
- $0.20 – $1.79
- YTD
- +28.42%
- IV Rank (30D)
- 16.94
- Straddle Price
- $2.90
- P/C Vol Ratio
- 0.15
- Market Cap
- $0.1B
- Open
- $1.07
- Day Range
- $1.03 – $1.10
- Volume
- 2,289,264
- Prev Close
- $1.11
Fair Value
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.78 |
| Cost of Equity (CAPM) | 14.77% (VRP-adj) |
| WACC | 12.64% |
| Volatility Risk Premium | +18.5pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | 940.6% |
| Book / Price | 7.5% |
| Debt / Equity | 2.73 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $0.70 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $1.10 |
| Bollinger Width / SMA20 | 8271.2% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Blended Fair Value
—
Deviation
—
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | n/a | 0% | |
| Peer P/S | n/a | 0% | |
| Market Anchor (SMA50) | $0.70 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.1B
- Employees
- 21
- List Date
- 2015-10-01
- CIK
- 0001472091
- Next Earnings
- 2026-11-12 (After-Close)
- EPS Forecast
- ($0.11) (2 est.)
- Headquarters
- Princeton, NJ
- Homepage
- https://www.pdsbiotech.com
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developi…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 33.77% | -29.30% | -21.56% | 3.88% | -5.20% | -0.05% | -3.08% |
| Feb | 12.15% | -1.97% | -7.05% | 17.26% | -16.35% | -18.30% | -2.38% |
| Mar | 5.81% | 4.74% | -20.75% | -39.91% | -1.65% | -12.57% | -10.72% |
| Apr | 21.44% | -11.09% | 0.33% | -16.67% | 29.63% | 60.48% | 14.02% |
| May | 109.62% | -31.94% | 57.05% | -17.45% | 3.76% | 10.13% | 21.86% |
| Jun | 15.56% | -1.62% | -49.19% | 0.86% | -5.67% | -22.71% | -10.46% |
| Jul | -13.81% | 15.99% | 14.53% | 17.49% | -12.30% | -21.07% | 0.14% |
| Aug | 41.62% | 0.72% | 3.16% | -0.93% | 13.76% | -70.04% | -1.95% |
| Sep | -2.61% | -29.62% | -16.39% | 26.49% | -19.20% | 267.99% | 37.78% |
| Oct | -15.63% | 59.76% | -11.28% | -12.60% | -8.32% | 50.83%* | 10.46% |
| Nov | -21.39% | 64.18% | 25.84% | -31.56% | -17.46% | -- | 3.92% |
| Dec | -9.90% | 34.97% | -5.33% | -24.19% | 7.26% | -- | 0.56% |
| Total | 231.72% | 25.79% | -51.70% | -66.09% | -35.25% | 28.00% | 22.08% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $1.10
SMA 50: $0.70
SMA 200: $0.82
Current: $1.06
EMA 12: $1.12
EMA 26: $1.02
MACD: 0.1059 | Signal: -0.0389
BULLISH
ADX (14): 51.48
STRONG TREND
+DI: 36.50
−DI: 18.11
Momentum Oscillators
RSI (14): 51.88
NEUTRAL
Stoch %K: 26.81
Stoch %D: 33.64
Williams %R: -81.46
Volume & Volatility
BB Upper: $1.61
BB Lower: $0.60
NEUTRAL
OBV: 1,127,078,936
Vol SMA 20: 11,661,443
Vol ROC: -85.11%
ATR: $0.18
True Range: $0.08
HV 20: 260.6%
HV 30: 288.4%
HV 60: 314.1%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall assessment: NEUTRAL (Confidence level: 6/10)
Key drivers:
- Recent positive news headlines highlighting cancer cure developments and company announcements
- Strong technical signals from momentum oscillators and Bollinger Bands
- High volatility, indicating a high-risk stock
Primary risks:
- Bearish MACD signal and negative trend indicators
- High beta and low correlation with the market
2-3 sentence investment thesis: PDSB is a highly volatile biotech company with significant upside potential due to its cancer cure developments. However, caution is advised due to its high risk profile and recent bearish technical signals.
Recent news sentiment impact: Positive news headlines have contributed to the stock's recent gains, but it remains crucial to assess the underlying technical signals.
Technical Analysis
Trend Direction: Short-term (1-4 weeks) - BEARISH, Medium-term (1-3 months) - NEUTRAL, Long-term (3-12 months) - BULLISH
Support/Resistance Levels: SMA 20 ($1.08), SMA 50 ($1.11), and Upper Bollinger Band ($1.23)
Momentum Signals: RSI interpretation: Neutral (41.74) MACD signal: Bearish (-0.03 / Signal: -0.02 / Histogram: -0.01) Bollinger Bands position: Oversold
Volume Analysis: Volume SMA 20 (1023373.30), On-Balance Volume (OBV) (-8463149.31), and Volume Rate of Change (-30.19%)
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines highlighting cancer cure developments and company announcements.
Sentiment Assessment: Aggregate news sentiment is POSITIVE.
Catalyst Identification: Upcoming earnings reports and product launches may drive further growth.
Market Narrative: Recent positive news has driven the stock's gains, but caution is advised due to high volatility and bearish technical signals.
Risk & Volatility Assessment
Beta Interpretation: High risk relative to market (beta 2.96).
Volatility Regime: Current vs historical volatility levels: High (112.6% HV20) indicating a highly volatile stock.
Options Market Signals: IV rank: Low, put/call ratios: Bullish sentiment, unusual activity: None.
Downside Protection: Support levels and risk management considerations:
- SMA 20 ($1.08)
- Bollinger Bands Lower Band ($0.93)
Market Context & Positioning
Sector Performance: Relative strength vs sector/market: Strong performer in the biotech sector.
Institutional Activity: Volume patterns suggesting institutional interest: High (90 calls vs 2 puts).
Correlation Analysis: How stock moves relative to market: Low correlation (0.37) indicating a high-risk stock.
Relative Valuation: Position within trading range:
- Lower Band ($0.93)
- Middle Band ($1.08)
Key Levels & Action Items
Critical Price Levels: Support/resistance levels:
- SMA 20 ($1.08)
- SMA 50 ($1.11)
- Upper Bollinger Band ($1.23)
Breakout/Breakdown Levels: Technical levels that could trigger significant moves:
- Oversold RSI (41.74) indicating potential bounce
- Bullish crossover of MACD signal
Time-Sensitive Catalysts: Earnings reports and product launches may drive further growth.
Risk Management: Stop-loss levels and position sizing considerations:
- SMA 20 ($1.08)
- Bollinger Bands Lower Band ($0.93)
Data Interpretation:
- RSI: Neutral (41.74)
- MACD: Bearish (-0.03 / Signal: -0.02 / Histogram: -0.01)
- Moving Averages: Price above SMA 20 and SMA 50 indicating uptrend
- Bollinger Bands: Price touching lower band indicating oversold
News Impact Assessment:
- Positive News: Fast-Tracking the $537B Cancer Cure, PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering
- Negative News: None reported
- Neutral News: PDSB Loss Improves as Costs Drop
Risk Assessment Criteria:
- High Risk: Beta 2.96, high volatility (112.6% HV20), negative news sentiment, technical breakdown
- Medium Risk: Beta 0.8-1.5, moderate volatility, mixed signals
- Low Risk: Beta <0.8, low volatility, positive fundamentals, strong technical support
Output Format Requirements:
- Be Objective: Present both bullish and bearish cases.
- Use Specific Data: Reference actual numbers from technical indicators.
- Highlight Conflicts: Note when technical and news signals diverge.
- Assess Data Quality: Comment on data completeness and reliability.
- No Buy/Sell Advice: Focus on risk/reward analysis only.
- Quantify Confidence: Rate analysis confidence based on data quality and signal clarity.
Data Quality Flags: Flag for missing earnings data and highlight the recent bearish MACD signal.
Generated
News
All PDSB news →
Earnings History
16 of 19 under expected move
Avg Expected Move
268.64%
Avg Actual Move
5.67%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-08-12 | After-Close | 11.02% | 2.20% | 0.20x | Within |
| 2021-11-10 | After-Close | 12.75% | 2.94% | 0.23x | Within |
| 2022-05-11 | After-Close | 35.90% | 1.86% | 0.05x | Within |
| 2022-08-08 | After-Close | 17.34% | 2.50% | 0.14x | Within |
| 2022-11-14 | After-Close | 16.43% | 22.95% | 1.40x | Exceeded |
| 2023-03-28 | After-Close | 43.08% | 2.91% | 0.07x | Within |
| 2023-05-15 | After-Close | 13.42% | 2.31% | 0.17x | Within |
| 2023-08-14 | After-Close | 10.13% | 10.32% | 1.02x | Exceeded |
| 2023-11-14 | After-Close | 19.42% | 1.44% | 0.07x | Within |
| 2024-03-27 | After-Close | 34.03% | 2.86% | 0.08x | Within |
| 2024-05-15 | After-Close | 50.00% | 0.86% | 0.02x | Within |
| 2024-08-13 | Pre-Market | 17.21% | 0.00% | 0.00x | Within |
| 2024-11-14 | Pre-Market | 10.87% | 18.48% | 1.70x | Exceeded |
| 2025-03-27 | After-Close | 250.00% | 0.80% | 0.00x | Within |
| 2025-05-14 | Pre-Market | 133.06% | 3.15% | 0.02x | Within |
| 2025-08-13 | After-Close | 175.19% | 3.45% | 0.02x | Within |
| 2025-11-12 | After-Close | 98.57% | 12.33% | 0.13x | Within |
| 2026-03-30 | After-Close | 85.40% | 12.77% | 0.15x | Within |
| 2026-08-12 | After-Close | 4070.25% | 3.64% | 0.00x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
PDSB Options Activity & IV Rank
PDSB IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 209.2%
7-DTE IV: 150.1%
Expected Move: $2.90
7-DTE Move: $0.40
Days to Exp: 32 (2026-11-27)
Options Flow
Call Volume: 124
Put Volume: 19
P/C Volume: 0.153
BULLISH
Call OI: 219
Put OI: 108
P/C OI: 0.493
Total OI: 327
ATM Options Pricing
ATM Call: $0.40
ATM Put: $2.50
Call %: 37.4%
Put %: 233.6%
Chain Summary
Chain Volume: 3,609
Chain OI: 46,090
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 18th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
18%
vs own history
GEX tilt
-0.03
OI-weighted, today
Vanna tilt
+0.23
δ-sensitivity to IV
Charm tilt
-0.07
δ-decay vs time
? What is this?
· 10 ATM contracts, 11k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 150.1% / Wing —
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 305.5% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)11.4LowOct 26
IV Rank (30 DTE)16.9LowOct 26
Straddle Price (30 DTE)$2.90Oct 26
Beta Analysis
Risk Metrics
Beta: 2.8631
Alpha: 129.28%
Correlation: 0.2091
R-Squared: 4.4%
Stock Volatility: 174.5%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own PDSB
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $285K | #5113 of 6285 | new | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $222K | #2861 of 3138 | +14.2% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $24K | #3674 of 4729 | 0.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
PDSB Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 48,663,148 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
3 filers$442.65K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Caption Management, LLC | $281.16K | 63.52% | 2026-06-30 |
| 2 | Simplex Trading, LLC Custodian | $139.90K | 31.61% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $21.59K | 4.88% | 2026-06-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|
PDSB Insider Trading (Form 4)
Latest: 2026-10-21Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-21 | John Andrew Dawson | Director | Grant (A) | +22,700 opt | — | EDGAR | |
| 2026-10-20 | Bruce Wendel | Director | Grant (A) | +22,700 opt | — | EDGAR | |
| 2026-10-20 | Deborah Ramsdell | Director | Grant (A) | +22,700 opt | — | EDGAR | |
| 2026-03-03 | Gregory Conn | Chief Scientific Officer | Grant (A) | +150,000 opt | — | EDGAR | |
| 2026-03-03 | Frank Bedu-Addo | President/CEO | Grant (A) | +548,782 opt | — | EDGAR | |
| 2026-03-03 | Stephan Toutain | Chief Operating Officer | Grant (A) | +300,000 opt | — | EDGAR | |
| 2026-03-03 | Lars Boesgaard | Chief Financial Officer | Grant (A) | +300,000 opt | — | EDGAR | |
| 2026-03-03 | Kamil Ali-Jackson | Director | Grant (A) | +54,876 opt | — | EDGAR | |
| 2026-03-03 | Ilian Iliev | Director | Grant (A) | +54,876 opt | — | EDGAR | |
| 2026-03-03 | Gregory Gene Freitag | Director | Grant (A) | +54,876 opt | — | EDGAR | |
| 2026-03-03 | Kirk V. Shepard | Chief Medical Officer | Grant (A) | +300,000 opt | — | EDGAR | |
| 2026-03-03 | Stephen C. Glover | Director | Grant (A) | +54,876 opt | — | EDGAR | |
| 2026-03-03 | Spencer D. Brown | Senior VP, General Counsel | Grant (A) | +300,000 opt | — | EDGAR | |
| 2026-03-03 | Otis W Brawley | Director | Grant (A) | +54,876 opt | — | EDGAR | |
| 2025-07-25 | Kirk V. Shepard | Chief Medical Officer | Grant (A) | +150,000 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
PDSB Insider Holdings
4 insiders · @ $1.06
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Frank Bedu-Addo | President/CEO | 690,866 | $735.8K | $0 | 9 | 2026-03-03 |
| 2 | Stephen C. Glover | Director | 78,851 | $84.0K | $75.0K | 10 | 2026-03-03 |
| 3 | Gregory Gene Freitag | Director | 61,213 | $65.2K | $75.0K | 10 | 2026-03-03 |
| 4 | Kamil Ali-Jackson | Director | 11,764 | $12.5K | $100.0K | 8 | 2026-03-03 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
PDSB Board & Officers
As of SEC filings through Oct 21, 2026Directors 11
- Frank Bedu-Addo · since Mar 15, 2019
- Gregory Gene Freitag · since Mar 15, 2019
- Stephen C. Glover · since Apr 2, 2019
- Kamil Ali-Jackson · since Feb 21, 2020
- Ilian Iliev · since Apr 8, 2020
- Otis W Brawley · since Nov 3, 2020
- Arnold James Banaag · since Sep 14, 2026
- Patrick Soon-Shiong · since Sep 14, 2026
- Bruce Wendel · since Oct 18, 2026
- Deborah Ramsdell · since Oct 18, 2026
- John Andrew Dawson · since Oct 18, 2026
Officers 7
- Frank Bedu-Addo · President/CEO · since Mar 15, 2019
- Lars Boesgaard · Chief Financial Officer · since Dec 4, 2023
- Gregory Conn · Chief Scientific Officer · since Mar 15, 2019
- Kirk V. Shepard · Chief Medical Officer · since Jan 22, 2024
- Stephan Toutain · Chief Operations Officer · since May 1, 2024
- Spencer D. Brown · Senior VP, General Counsel · since Jun 1, 2022
- Janetta Trochimiuk · Principal Accounting Officer · since Mar 23, 2020
10% owners 2
- Nant Capital, LLC (entity) · since Sep 14, 2026
- Patrick Soon-Shiong · since Sep 14, 2026
Changes in the last 10 years (49)
| Oct 18, 2026 | John Andrew Dawson became a director |
| Oct 18, 2026 | Deborah Ramsdell became a director |
| Oct 18, 2026 | Bruce Wendel became a director |
| Sep 14, 2026 | Patrick Soon-Shiong became a director |
| Sep 14, 2026 | Patrick Soon-Shiong became a 10% owner |
| Sep 14, 2026 | Nant Capital, LLC became a 10% owner |
| Sep 14, 2026 | Arnold James Banaag became a director |
| Apr 22, 2025 | The company announced the departure of Richard Sykes from the board in an SEC filing |
| May 1, 2024 | Stephan Toutain became Chief Operations Officer |
| Jan 22, 2024 | The company announced the departure of Lauren Wood as Chief Medical Officer in an SEC filing |
| Jan 22, 2024 | Kirk V. Shepard became Chief Medical Officer |
| Dec 4, 2023 | Lars Boesgaard became Chief Financial Officer |
| Nov 21, 2023 | The company announced the departure of Matthew C Hill as Chief Financial Officer in an SEC filing |
| Jun 1, 2022 | Spencer D. Brown became Senior VP, General Counsel |
| Oct 18, 2021 | Matthew C Hill became Chief Financial Officer |
| Jun 21, 2021 | DeLyle W Bloomquist reported in an SEC filing no longer being a director |
| Jun 21, 2021 | DeLyle W Bloomquist reported in an SEC filing no longer being a 10% owner |
| Jan 1, 2021 | Seth Van Voorhees became Chief Financial Officer |
| Nov 3, 2020 | Otis W Brawley became a director |
| Jun 25, 2020 | Frank Bedu-Addo no longer listed as a 10% owner in SEC filings |
| Jun 23, 2020 | Michael N. King became Interim Chief Financial Office |
| Apr 8, 2020 | Ilian Iliev became a director |
| Mar 23, 2020 | Janetta Trochimiuk became Principal Accounting Officer |
| Feb 21, 2020 | Kamil Ali-Jackson became a director |
| Jun 7, 2019 | Andrew Saik first listed as a director in an SEC filing |
| Apr 2, 2019 | Stephen C. Glover became a director |
| Mar 18, 2019 | Rosemary A Crane reported in an SEC filing no longer being a director |
| Mar 18, 2019 | R. Loch Macdonald reported in an SEC filing no longer being a director |
| Mar 18, 2019 | Liam Ratcliffe reported in an SEC filing no longer being a director |
| Mar 18, 2019 | Isaac Blech reported in an SEC filing no longer being a director |
| Mar 18, 2019 | Brian A Leuthner reported in an SEC filing no longer being a director |
| Mar 18, 2019 | Brian A Leuthner reported in an SEC filing no longer being President and CEO |
| Mar 15, 2019 | Richard Sykes became a director |
| Mar 15, 2019 | Lauren Wood became Chief Medical Officer |
| Mar 15, 2019 | Gregory Gene Freitag became a director |
| Mar 15, 2019 | Gregory Conn became Chief Scientific Officer |
| Mar 15, 2019 | Frank Bedu-Addo became a director |
| Mar 15, 2019 | Frank Bedu-Addo became a 10% owner |
| Mar 15, 2019 | Frank Bedu-Addo became President/CEO |
| Mar 15, 2019 | DeLyle W Bloomquist became a director |
| Mar 15, 2019 | DeLyle W Bloomquist became a 10% owner |
| Jan 3, 2019 | Alyssa Wyant reported in an SEC filing no longer being SVP Regulatory Affairs |
| Dec 31, 2018 | Herbert J Faleck reported in an SEC filing no longer being Chief Medical Officer |
| Dec 31, 2018 | Albert N Marchio II reported in an SEC filing no longer being Chief Accounting & Adm Officer |
| Jun 20, 2018 | R. Loch Macdonald no longer listed as Chief Scientific Officer in SEC filings |
| Oct 31, 2017 | Andrew Saik became Chief Financial Officer |
| Sep 18, 2017 | Rosemary A Crane became a director |
| Aug 24, 2017 | Albert N Marchio II listed as Chief Accounting & Adm Officer (previously Chief Accounting & Ops Officer) in SEC filings |
| Feb 21, 2017 | Alyssa Wyant became SVP Regulatory Affairs |
Not reported recently (12)
- Seth Van Voorhees · Last reported as Chief Financial Officer in an SEC filing dated Jun 17, 2021
- Michael N. King · Last reported as Interim Chief Financial Office in an SEC filing dated Dec 9, 2020
- Andrew Saik · Last reported as Chief Financial Officer in an SEC filing dated Feb 19, 2020
- James J Loughlin · Last reported as a director in an SEC filing dated Jul 1, 2019
- Robert J. Spiegel · Last reported as a director in an SEC filing dated Mar 18, 2019
- Sol J Barer · Last reported as a director in an SEC filing dated Mar 18, 2019
- W Bradford Middlekauff · Last reported as Senior VP, GC and Secretary in an SEC filing dated Mar 18, 2019
- Kurt G Conti · Last reported as a director in an SEC filing dated Mar 30, 2018
- Daniel Brennan · Last reported as Chief Operating Officer in an SEC filing dated Mar 5, 2018
- James Healy · Last reported as a director in an SEC filing dated Jun 21, 2017
- Alpaslan Yaman · Last reported as V.P., Technical Ops. & Mfg. in an SEC filing dated Mar 15, 2017
- Andrew J. Einhorn · Last reported as Chief Financial Officer in an SEC filing dated Mar 13, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
3 ETFs hold PDSB
3 shown · $1.41M total exposure · 0.02% AUM-weighted avg weight
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.67
TTM Revenue
—
TTM Net Income
$-33.36M
TTM Op. Cash Flow
$-23.09M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | — | $-7.35M | $-0.13 | $-4.37M |
| Q4 '25 | 2025-12-31 | — | $-7.56M | $-0.14 | $-3.70M |
| Q3 '25 | 2025-09-30 | — | $-9.01M | $-0.19 | $-5.92M |
| Q2 '25 | 2025-06-30 | — | $-9.43M | $-0.21 | $-9.10M |
| Q1 '25 | 2025-03-31 | — | $-8.49M | $-0.21 | $-9.03M |
| Q4 '24 | 2024-12-31 | — | $-7.95M | $-0.21 | $-8.23M |
| Q3 '24 | 2024-09-30 | — | $-10.73M | $-0.29 | $-8.00M |
| Q2 '24 | 2024-06-30 | — | $-8.33M | $-0.23 | $-8.86M |
| Q1 '24 | 2024-03-31 | — | $-10.60M | $-0.30 | $-9.94M |
| Q4 '23 | 2023-12-31 | — | $-10.90M | $-0.35 | $-8.46M |
| Q3 '23 | 2023-09-30 | — | $-10.85M | $-0.35 | $-7.18M |
| Q2 '23 | 2023-06-30 | — | $-11.53M | $-0.37 | $-4.81M |
Q1 2026 • period ending 2026-03-31 • filed 2026-05-14
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
13.31
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-856.9%
ROA
-135.2%
Div Yield
0.00%
FCF Yield
-44.56%
Debt/Equity
2.73
Current Ratio
—
Market Cap
$51.83M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
2.77M
SI % of Float
5.29%
Days to Cover
1.00
Short Vol Ratio
29.2%
Free Float
52.38M
Float %
93.6%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-14